The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
The GMP certificate is valid for three years until April 2024.
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.790.88 crores for the 12 months period ended March 31, 2021
The company has posted net profit of Rs.200.08 crores for the 12 months period ended March 31, 2021
It reported total income of Rs.865.93 crores during FY 2020-21
It reported total income of Rs.3008.74 crores during FY 2020-21
The company reported total income of Rs.581.06 crores during FY 2020-21
The company reported total income of Rs.1106.80 crores during the 12 months period ended March 31, 2021 a
The company has reported total income of Rs.2663.47 crores during FY 2020-21
The company has reported total income of Rs.1871.12 crores during FY 2020-21
For the year ended March 31, 2021, consolidated revenue was at Rs. 10,943.9 crores as against Rs. 10,641 crores, recording an increase of 2.8% over the previous corresponding period
To be used by the chemical industry, it helps eliminate the challenges posed by the chemical when sourced through traditional processes
The new agreement will see at least 15,000 tonnes of PE and PP rich plastic feedstock diverted away from incineration and into recycling annually
Consolidated FY21 revenue grew by 24% and crossed Rs. 5,800 crores whereas net profit jumped by 357% and crossed Rs. 400 crores
The agreement applies to the drum business for TFE, TFA, TFAH, TA and TAA in Germany, France, Switzerland and Austria
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
PAT increased from Rs. 10.8 crores in FY20 to Rs. 49.1 crores in FY21 and PAT margin expanded from 2% to 7.2% YoY
Subscribe to our newsletter & stay updated.
